|
Title
|
|
|
|
BRAVISSIMO : 12-month results from a large scale prospective trial
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| The BRAVISSIMO study is a prospective, non-randomized, multi-center, multi-national, monitored trial, conducted at 12 hospitals in Belgium and 11 hospitals in Italy. This manuscript reports the findings up to the 12-month follow-up time point for both the TASC A&B cohort and the TASC C&D cohort. The primary endpoint of the study is primary patency at 12 months, defined as a target lesion without a hemodynamically significant stenosis on Duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR) within 12 months. Between July 2009 and September 2010, 190 patients with TASC A or TASC B aortoiliac lesions and 135 patients with TASC C or TASC D aortoiliac lesions were included. The demographic data were comparable for the TASC A/B cohort and the TASC C/D cohort. The number of claudicants was significantly higher in the TASC A/B cohort, The TASC C/D cohort contains more CLI patients. The primary patency rate for the total patient population was 93.1%. The primary patency rates at 12 months for the TASC A, B, C and D lesions were 94.0%, 96.5%, 91.3% and 90.2% respectively. No statistical significant difference was shown when comparing these groups. Our findings confirm that endovascular therapy, and more specifically primary stenting, is the preferred treatment for patients with TASC A, B, C and D aortoiliac lesions. We notice similar endovascular results compared to surgery, however without the invasive character of surgery. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
The journal of cardiovascular surgery. - Torino, 1960, currens
| |
|
Source (book)
|
|
|
|
CIRSE Congress, 2012, Lisbon, PORTUGAL
| |
|
Publication
|
|
|
|
Torino
:
Edizioni Minerva Medica
,
2013
| |
|
ISSN
|
|
|
|
0021-9509
[print]
1827-191X
[online]
| |
|
Volume/pages
|
|
|
|
54
:2
(2013)
, p. 235-253
| |
|
ISI
|
|
|
|
000318208200009
| |
|